Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis

Annals of the Rheumatic Diseases

Volumn 76, Issue 10, 2017, Pages 1662-1668

  Karras, Alexandre ^a,b   Pagnoux, Christian ^c   Haubitz, Marion ^d   De Groot, Kirsten ^e   Puechal, Xavier ^f   Tervaert, Jan Willem Cohen ^g   Segelmark, Marten ^h   Guillevin, Loic ^b,f   Jayne, David ⁱ  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c MOUNT SINAI HOSPITAL   (Canada)

^d KLINIKUM FULDA   (Germany)

^e Klinikum Offenbach   (Germany)

^f Hopital Cochin ^*  (France)

^g MAASTRICHT UNIVERSITY   (Netherlands)

^h LINKÖPING UNIVERSITY   (Sweden)

ⁱ UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CREATININE; CYCLOPHOSPHAMIDE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISOLONE; ANTIINFLAMMATORY AGENT; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGE; ANCA ASSOCIATED VASCULITIS; ANTIBODY SPECIFICITY; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DRUG EFFICACY; END STAGE RENAL DISEASE; FEMALE; HEMATOLOGIC DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY FUNCTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; REMISSION; TREATMENT DURATION; TREATMENT OUTCOME; ADVERSE EFFECTS; AGED; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; BLOOD; COMPARATIVE STUDY; COMPLICATION; GLOMERULUS FILTRATION RATE; KIDNEY FAILURE, CHRONIC; MAINTENANCE CHEMOTHERAPY; PROCEDURES; SECONDARY PREVENTION; SURVIVAL RATE; TIME FACTOR;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; AZATHIOPRINE; CREATININE; CYCLOPHOSPHAMIDE; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; PREDNISOLONE; PROSPECTIVE STUDIES; REMISSION INDUCTION; SECONDARY PREVENTION; SURVIVAL RATE; TIME FACTORS;

EID: 85024849963     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2017-211123     Document Type: Article

References (24)

1. Jennette JC, Falk RJ, Bacon PA, et al. Revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum 2012;65:1-11.
2. Flossmann O, Berden A, de Groot K, et al. Long-term patient survival in ANCAassociated vasculitis. Ann Rheum Dis 2011;70:488-94.
3. Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003;349:36-44.
4. Hilhorst M, van Paassen P, Tervaert JW, et al. Proteinase 3-ANCA vasculitis versus Myeloperoxidase-ANCA vasculitis. J Am Soc Nephrol 2015;26:2314-27.
5. Yates M, Watts RA, Bajema IM, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis 2016;75:1583-94.
6. Walsh M, Flossmann O, Berden A, et al. Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2012;64:542-8.
7. R obson J, Doll H, Suppiah R, et al. Damage in the anca-associated vasculitides: longterm data from the European vasculitis study group (EUVAS) therapeutic trials. Ann Rheum Dis 2015;74:177-84.
8. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. proposal of an international consensus conference. Arthritis Rheum 1994;37:187-92.
9. Luqmani RA, Bacon PA, Moots RJ, et al. Birmingham Vasculitis Activity score (BVAS) in systemic necrotizing vasculitis. QJM 1994;87:671-8.
10. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. modification of diet in Renal disease study group. Ann Intern Med 1999;130:461-70.
11. Exley AR, Bacon PA, Luqmani RA, et al. Development and initial validation of the vasculitis damage index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum 1997;40:371-80.
12. Specks U, Merkel PA, Seo P, et al. Efficacy of remission-induction regimens for ANCAassociated vasculitis. N Engl J Med 2013;369:417-27.
13. P agnoux C, Mahr A, Hamidou MA, et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med 2008;359:2790-803.
14. Hiemstra TF, Walsh M, Mahr A, et al. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA 2010;304:2381-8.
15. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005;352:351-61.
16. Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 2014;371:1771-80.
17. Sanders JS, de Joode AA, DeSevaux RG, et al. Extended versus standard azathioprine maintenance therapy in newly diagnosed proteinase-3 anti-neutrophil cytoplasmic antibody-associated vasculitis patients who remain cytoplasmic anti-neutrophil cytoplasmic antibody-positive after induction of remission: a randomized clinical trial. Nephrol Dial Transplant 2016;31:1453-9.
18. de Joode AA, Sanders JS, Stegeman CA. Renal survival in proteinase 3 and myeloperoxidase ANCA-associated systemic vasculitis. Clin J Am Soc Nephrol 2013;8:1709-17.
19. Slot MC, Tervaert JW, Franssen CF, et al. Renal survival and prognostic factors in patients with PR3-ANCA associated vasculitis with renal involvement. Kidney Int 2003;63:670-7.
20. Hogan SL, Falk RJ, Chin H, et al. Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med 2005;143:621-31.
21. de Joode AA, Sanders JS, Rutgers A, et al. Maintenance therapy in antineutrophil cytoplasmic antibody-associated vasculitis: who needs what and for how long? Nephrol Dial Transplant 2015;30:i150-8.
22. Slot MC, Tervaert JW, Boomsma MM, et al. Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis. Arthritis Rheum 2004;51:269-73.
23. Wada T, Hara A, Arimura Y, et al. Risk factors associated with relapse in Japanese patients with microscopic polyangiitis. J Rheumatol 2012;39:545-51.
24. R obson J, Doll H, Suppiah R, et al. Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European vasculitis study group trials. Rheumatology 2015;54:471-81.